Printer Friendly

QUIDEL COMMENTS ON RECENT PRESS ARTICLE

 SAN DIEGO, Aug. 10 /PRNewswire/ -- QUIDEL Corporation (NASDAQ: QDEL), a leading developer and marketer of rapid diagnostic tests, today issued the following statement commenting on an article appearing in the Aug. 16, 1993 edition of Business Week.
 The article highlighted the profit progress of QUIDEL over the last two years by way of introducing new rapid testing diagnostic products for physicians and consumers. The article also indicated the company made forecasts regarding sales and profits from its SafePlan(TM) test which is being developed by QUIDEL and its worldwide marketing partner for this product, AKZO.
 Commenting on the article, Scott L. Glenn, chairman and chief executive officer of QUIDEL, said, "In our discussions with the press and analysts concerning the SafePlan product, we have given wide-ranging estimates of the potential size of the market opportunity that SafePlan addresses. However, due to the risks associated with the remaining uncertainties, including regulatory approvals, decisions internal to AKZO, and the ultimate market acceptance of this new type of product, we are not in a position to make public sales and earnings forecasts." Glenn continued, "While we continue to be optimistic about the prospects of SafePlan, given the brevity of the QUIDEL story, the article compressed a wide range of possible sales and earnings scenarios into a very optimistic case."
 Glenn went on to say, "We feel the progress we have made on the development of SafePlan to date is promising." "We have received two patents for technology related to this product and consumer test results have been completed which encourages QUIDEL to move forward and file a 510(k) submission with the United States Food and Drug Administration (FDA). While it is possible that the product could be introduced in selected European markets as early as our fourth quarter (January-March, 1994), we have not, at this point, reached consensus or assurance on several issues including market strategies and introduction dates with our partner, AKZO."
 QUIDEL Corporation develops, manufactures and markets rapid immunodiagnostic products for family planning and family care. These products, which provide simple, accurate and cost-effective diagnoses in the areas of human fertility, infectious diseases, allergy and autoimmune disorders, are designed for use in the physician's office, clinical laboratory and home testing markets.
 -0- 8/10/93
 /CONTACT: Scott L. Glenn, chairman and CEO, 619-552-7900, or Mark Francois, director-investor relations, 619-552-7931, both of QUIDEL/
 (QDEL)


CO: QUIDEL Corporation ST: California IN: MTC SU:

LG-SH -- NY028 -- 1129 08/10/93 10:39 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 1993
Words:410
Previous Article:STONE & WEBSTER FORMS TRANSPORTATION SERVICES DIVISION
Next Article:SOUTHERN NATIONAL BANK 'A-/F-1' DEPOSITS ON FITCHALERT NEGATIVE -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters